That is worth saying up front because GT20029 has picked up the kind of forum momentum that usually attaches to drugs a year from pharmacy shelves. It is not a year from pharmacy shelves. It is not approved anywhere, no phase 3 trial is registered, and the company developing it — Suzhou-based Kintor Pharmaceutical — has spent the last two years saying the next trial is coming. What follows is what the drug actually is, what the one efficacy trial found once you read past the press release, and what a man losing hair should do in the meantime.
What GT20029 is, and why the mechanism is genuinely new
Male pattern hair loss runs on androgens. Dihydrotestosterone binds the androgen receptor in susceptible follicles, and over years those follicles miniaturise into the fine vellus hairs you see at a thinning crown [2]. Every effective drug in this space attacks some part of that chain. Finasteride cuts DHT production systemically. Pyrilutamide — Kintor's other hair-loss compound, KX-826 — sits on the receptor and blocks it.
GT20029 does something different. It is a PROTAC, a proteolysis-targeting chimera: a two-ended molecule that grabs the androgen receptor with one end and an E3 ubiquitin ligase with the other, which tags the receptor for the cell's own disposal machinery [3]. The receptor is not blocked; it is removed. In principle, a degrader can keep working at concentrations where a blocker would be outcompeted, because one molecule can tag receptor after receptor.
PROTACs are big molecules, which is usually a problem — they get into cells poorly and into skin worse. Kintor's pitch turns that into a feature: if very little crosses the skin, very little reaches the blood, and the sexual side effects that make men nervous about finasteride should not have a route to happen [6]. Kintor describes it as the first topical PROTAC to complete phase 2 anywhere [6]. A 2026 review from the University of Miami group led by Antonella Tosti lists it alongside clascoterone as one of the topical androgen-receptor approaches worth watching [8]. That is the right level of enthusiasm: worth watching.
The phase 2 trial, read carefully
The trial ran at 12 Chinese hospitals from April 2023 to April 2024, enrolling 180 men aged 18 and over with Norwood IIIv to V hair loss [1][2]. Men were split equally into six arms of 30: GT20029 0.5% or 1.0% applied daily, the same two strengths applied twice weekly (Mondays and Thursdays), and a matching placebo for each schedule [1]. The primary endpoint was the change in non-vellus hair count per square centimetre in a target area at week 12.
Kintor's headline figures [3], repeated in its 2026 interim results [6]:
| Arm | Change from baseline, week 12 | Difference vs its placebo |
|---|---|---|
| 0.5% once daily | +16.80 hairs/cm² | +6.69 (p < 0.05) |
| 1.0% twice weekly | +11.94 hairs/cm² | +7.36 (p < 0.05) |
| 1.0% once daily | Not reported in the release | Not reported as beating placebo in the paper |
| 0.5% twice weekly | Not reported in the release | Not reported as beating placebo in the paper |
The peer-reviewed paper, published in the Journal of Dermatological Treatment in December 2025, adds the part the release left out [2]. All four active arms grew hair compared to baseline. Only two of the four are reported as beating their placebo groups — 0.5% daily (p = 0.032) and 1.0% twice weekly (p = 0.023). Hair width also improved significantly in the 1.0% twice-weekly arm. Adverse event rates were similar across all six groups and mostly mild.
Three things in that table matter more than the headline.
The placebo arms grew a lot of hair. The release does not print the placebo numbers, but subtracting gives them: by our arithmetic, the daily placebo group gained about 10 hairs/cm² and the twice-weekly placebo group about 4.6. A daily placebo arm gaining ten hairs per square centimetre in twelve weeks is a big number, and it means two-thirds of what the 0.5% daily arm achieved was not the drug. Strong placebo response is common in hair-count trials — daily scalp application, attention and photography all move the count — but it is why the vs-placebo column, not the from-baseline column, is the one to read.
The daily dose-response runs backwards. If GT20029 at 0.5% daily works, 1.0% daily should work at least as well. It did not separate from placebo. Kintor reports a dose-response within the twice-weekly cohort [6] and says nothing about the daily one. With 30 men per arm that can be noise, but it is the kind of noise a phase 3 exists to resolve, and it is clearly the most important unanswered question in the dataset.
The effect is modest. An edge over placebo of roughly 7 hairs/cm² at 12 weeks is real, and it is early — finasteride's own label says three months or more of daily use is generally needed before any benefit shows [7]. But it is not the kind of number that lets anyone call GT20029 better than what already exists. The finasteride label reports a 107-hair difference compared to placebo at one year in a 5.1 cm² circle [7], which works out to about 21 per cm² by our arithmetic. Different method, different population, different duration — the comparison is not like for like, and we are not offering it as one. It is offered to show the scale of what GT20029 would eventually need to match.
Kintor itself now calls this trial "phase IIa" and plans a "phase IIb/III" next [6]. The April 2024 release said phase III [3]. Adding a IIb component is a quiet acknowledgement that the dose question is not settled.
The safety case is the real selling point
Where GT20029 looks strongest is the thing it was designed for: staying in the skin.
In the 92-person China phase 1, single topical doses produced no detectable drug in the blood at any time point (below 0.001 ng/mL), and after 14 days of repeated dosing mean peak concentrations stayed under 0.05 ng/mL in every cohort [4][6]. All treatment-related adverse events were grade 1. The 123-person US phase 1, which included men with hair loss and people with acne in its multiple-dose stage, found peak concentrations hovering near the detection limit and never above 0.015 ng/mL; the common side effects were application-site dryness, itching, burning and pain, with no serious adverse events [5][6]. In the phase 2, Kintor reports no sexual adverse events at all [3].
Compare that to finasteride, which suppresses serum DHT by 65% within 24 hours [7] and carries labelled rates of decreased libido of 1.8% vs 1.3% on placebo, erectile dysfunction of 1.3% vs 0.7%, and ejaculation disorder of 1.2% vs 0.7% in year-one trials [7]. Those numbers are small, but they are the reason a lot of men never start. A topical that does not reach the bloodstream would remove the objection rather than shrink it.
Two cautions. Every safety statement above comes from Kintor's own trials and disclosures; the phase 2 paper's authors include three Kintor employees [2]. And 12 weeks in 120 treated men is not a safety database. Finasteride's sexual side-effect question took years and thousands of patients to characterise. GT20029 has not been tested long enough for anyone to know what a two-year course looks like.
Where GT20029 stands now, and what to use instead
As of Kintor's interim results for the six months to June 2026, published in August, the company "plan[s] to initiate the phase IIb/III clinical trial of GT20029 for male AGA in China in the second half of 2026," with a US phase 2 also planned [6]. The same language about a China phase 3 and a US phase 2 appeared in April 2024 [3]. As of this writing, ClinicalTrials.gov lists exactly three GT20029 studies — two phase 1 trials and the phase 2 — all completed, none recruiting. A separate acne phase 2 in China met its primary endpoint [6].
For a sense of timing, Kintor's own projection for KX-826 is useful: phase 3 topline in March 2026, a Chinese filing in the second half of 2026, and approval hoped for in the second half of 2027 [6]. GT20029 has not started that phase 3. Even on an optimistic run, China approval is years away and a US approval further still. Treat that as our estimate, not the company's.
It also cannot be bought legitimately. Anything sold online under the GT20029 name is not the trial drug, has not been through the trial, and is not something we would put on a scalp.
So the practical answer for a man in his 30s, 40s or 50s noticing a wider part is unglamorous: waiting for GT20029 is not worth the hair you lose in the meantime. Miniaturised follicles are far easier to hold than to bring back, and the drugs that already exist have years of data behind them. Our view:
- Finasteride remains the better choice for most men who can tolerate it — the only treatment here with five-year hair-count data [7]. If the systemic side effects are the worry, topical finasteride is the closest available thing to what GT20029 is promising; our topical dutasteride vs topical finasteride comparison covers the trade-offs, and the full head-to-head is in finasteride vs dutasteride.
- Minoxidil works by a different route and pairs with any of the above. Whether to take it orally or topically is its own decision — see oral vs topical minoxidil.
Getting a prescription is now a short online consult. Hims, Roman and Strut Health all offer finasteride and minoxidil, with Strut leaning toward compounded topical combinations. Maximus and MangoRx are two more telehealth options worth comparing on price and formulation. You can compare all hair-loss providers side by side, and our hair restoration hub covers the in-clinic options.
If GT20029 reaches phase 3 and the twice-weekly arm holds up across a few hundred men for a year, it could become the topical that finally ends the finasteride-anxiety argument. That is a real possibility. It is not a result yet.
Frequently asked questions
Is GT20029 approved by the FDA?
No. GT20029 is investigational and not approved in the US, China or anywhere else. It has completed two phase 1 safety trials and one 12-week phase 2 trial [4][5][2]. No phase 3 trial is registered.
When will GT20029 be available?
Nobody can say. Kintor plans a phase IIb/III in China starting in the second half of 2026 and a US phase 2 [6], but the same plans were announced in April 2024 [3]. Even if the trial starts on schedule, a China approval would be several years out and a US approval later still.
How does GT20029 compare to finasteride?
There is no head-to-head trial. GT20029 beat placebo by about 7 hairs/cm² at 12 weeks in its best arms [3]; finasteride's label reports a much larger difference compared to placebo at one year, measured differently [7]. GT20029's advantage is the safety profile — minimal blood levels and no sexual side effects reported so far [3][6] — not demonstrated superior regrowth.
Is GT20029 the same as pyrilutamide?
No. Both come from Kintor and both target the androgen receptor, but pyrilutamide (KX-826) blocks the receptor while GT20029 tags it for destruction [3][6]. Pyrilutamide is further along: Kintor's own filing describes a positive phase 3 readout in March 2026 and a planned China submission [6], though no result has been posted to the trial registry. Our pyrilutamide vs finasteride comparison covers it.
Does GT20029 cause sexual side effects?
None were reported in the phase 2 trial, and blood levels in phase 1 were at or near the limit of detection [3][4][5]. That is encouraging but comes from 12 weeks of data in about 120 treated men. Long-term safety is unknown.
What should I use while waiting for GT20029?
Finasteride, oral or topical, plus minoxidil remains the standard with the strongest evidence [7]. Starting now protects follicles that may not be recoverable later, which matters more than which drug eventually wins.
Sources
- [1] NCT06692465 — Phase II trial of GT20029 solution for androgenetic alopecia in Chinese adult males, ClinicalTrials.gov
- [2] Hu et al., Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study, Journal of Dermatological Treatment, 2025
- [3] Kintor Pharmaceutical, GT20029 China Phase II trial for AGA reached primary endpoint, April 21, 2024
- [4] NCT06468579 — Phase I safety, tolerability and PK of GT20029 gel and solution in healthy subjects (China), ClinicalTrials.gov
- [5] NCT05428449 — Phase I safety, tolerability and PK of topical GT20029 (US), ClinicalTrials.gov
- [6] Kintor Pharmaceutical, interim results announcement for the six months ended 30 June 2026, HKEX filing
- [7] Propecia (finasteride) US prescribing information, FDA
- [8] Agrawal, Dreifus and Tosti, Emerging pharmacotherapies for androgenetic alopecia, Expert Opinion on Pharmacotherapy, 2026
Alpha Health Finder Editorial Team
Editorial Team
The Alpha Health Finder editorial team researches and writes evidence-based men's health content. Articles are grounded in cited primary sources and reviewed against a fixed editorial standard before publication. We are a research and directory team — not your prescribing clinicians.
Looking for an online provider?
Find a qualified online provider — compare options vetted and reviewed by Alpha Health Finder.
One email a week. The research, not the hype.
What we published this week, what we changed our minds about, and what it means if you are on a protocol.
No spam, no selling your address. Unsubscribe in one click.




